Sotera Health (SHC) Soars 2.33% on Goldman Sachs Upgrade

Sotera Health (SHC) shares surged 2.33% today, reaching their highest level since February 2025 with an intraday gain of 3.04%.

The strategy of buying SHC shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 4.46% annualized return. This indicates a relatively stable performance, although the overall returns were modest due to the short holding period.

Goldman Sachs recently upgraded Sotera Health from a "neutral" rating to a "buy" rating, which likely contributed to the positive market sentiment. This upgrade, along with the reaffirmation of the company's full-year 2025 outlook, has bolstered investor confidence. Sotera Health projects net revenue growth of 4.0% to 6.0% and adjusted EBITDA growth of 4.5% to 6.5% for the year, despite facing recent earnings challenges and a net loss. The company is also considered significantly undervalued, with an estimated fair value of US$23.03, which adds to the optimism surrounding its stock performance.